Current Treatment Options in Oncology最新文献_第5页

Advancements in Melanoma Therapies: From Surgery to Immunotherapy 黑色素瘤疗法的进展：从手术到免疫疗法

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-27 DOI: 10.1007/s11864-024-01239-8

Neda Shajari, Behzad Baradaran, Mohammad Reza Tohidkia, Hadi Nasiri, Maryam Sepehri, Sepideh Setayesh, Leili Aghebati‐Maleki

{"title":"Advancements in Melanoma Therapies: From Surgery to Immunotherapy","authors":"Neda Shajari, Behzad Baradaran, Mohammad Reza Tohidkia, Hadi Nasiri, Maryam Sepehri, Sepideh Setayesh, Leili Aghebati‐Maleki","doi":"10.1007/s11864-024-01239-8","DOIUrl":"https://doi.org/10.1007/s11864-024-01239-8","url":null,"abstract":"Melanoma is defined as the most aggressive and deadly form of skin cancer. The treatment of melanoma depends on the disease stage, tumor location, and extent of its spread from its point of origin. Melanoma treatment has made significant advances, notably in the context of targeted and immunotherapies. Surgical resection is the main therapeutic option for earlystage melanoma, and it provides favourable outcomes. With disease metastasis, systemic treatments such as immunotherapy and targeted therapy become increasingly important. The identification of mutations that lead to melanoma has influenced treatment strategies. Targeted therapies focusing on these mutations offer improved response rates and fewer toxicities than conventional chemotherapy. Furthermore, developing immunotherapies, including checkpoint inhibitors and tumor-infiltrating lymphocyte (TIL) therapies, has demonstrated encouraging outcomes in effectively combating cancer cells. These therapeutic agents demonstrate superior effectiveness and a more tolerable side-effect profile, improving the quality of life for patients receiving treatment. The future of melanoma treatment may involve a multimodal approach consisting of a combination of surgery, targeted therapy, and immunotherapy adapted to each patient's profile. This approach may improve survival rates and health outcomes.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"47 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141785483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic Management of Advanced Adrenocortical Carcinoma 晚期肾上腺皮质癌的全身治疗

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-27 DOI: 10.1007/s11864-024-01249-6

Jeffery S. Russell

{"title":"Systemic Management of Advanced Adrenocortical Carcinoma","authors":"Jeffery S. Russell","doi":"10.1007/s11864-024-01249-6","DOIUrl":"https://doi.org/10.1007/s11864-024-01249-6","url":null,"abstract":"Adrenocortical cancer (ACC) is a rare and aggressive disease. Surgery has traditionally been the primary treatment for locally advanced disease with ongoing controversy around the optimal neoadjuvant and adjuvant treatment options. Unfortunately, local recurrence and the eventual development of metastatic disease is common and five-year survival rates are poor. While many trials have evaluated novel systemic agents to treat advanced adrenocortical cancer, only a few drugs have demonstrated any response at all. To date, only one drug, mitotane, is approved in the US for ACC and no regimen has clearly shown an increase in overall survival. In advanced metastatic or unresectable disease, data supports the first line regimen of EDP chemotherapy + mitotane as the primary treatment modality. In the second line, while data is limited, we would recommend consideration of immunotherapy using a PD(L)1 agent combined with a TKI/VEGF inhibitor or combination immunotherapy with PD1/CTLA-4 drugs. In all cases, we always prefer a clinical trial as available. This article reviews data from multiple studies evaluating novel systemic agents against ACC and discusses current systemic therapy combinations and ongoing clinical trials.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"76 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141776329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Small Cell Lung Cancer—An Update on Chemotherapy Resistance 小细胞肺癌--化疗耐药性的最新进展

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-27 DOI: 10.1007/s11864-024-01245-w

Qian Ying, Ruiyun Fan, Yili Shen, Boyi Chen, Jianhui Zhang, Qiuhui Li, Xuefei Shi

引用次数: 0

Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review 蒽环类药物诱发心脏毒性的精准治疗：最新综述

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-27 DOI: 10.1007/s11864-024-01238-9

Ziyu Kuang, Yuansha Ge, Luchang Cao, Xinmiao Wang, Kexin Liu, Jiaxi Wang, Xiaojuan Zhu, Min Wu, Jie Li

{"title":"Precision Treatment of Anthracycline-Induced Cardiotoxicity: An Updated Review","authors":"Ziyu Kuang, Yuansha Ge, Luchang Cao, Xinmiao Wang, Kexin Liu, Jiaxi Wang, Xiaojuan Zhu, Min Wu, Jie Li","doi":"10.1007/s11864-024-01238-9","DOIUrl":"https://doi.org/10.1007/s11864-024-01238-9","url":null,"abstract":"Anthracycline (ANT)-induced cardiotoxicity (AIC) is a particularly prominent form of cancer therapy-related cardiovascular toxicity leading to the limitations of ANTs in clinical practice. Even though AIC has drawn particular attention, the best way to treat it is remaining unclear. Updates to AIC therapy have been made possible by recent developments in research on the underlying processes of AIC. We review the current molecular pathways leading to AIC: 1) oxidative stress (OS) including enzymatic-induced and other mechanisms; 2) topoisomerase; 3) inflammatory response; 4) cardiac progenitor cell damage; 5) epigenetic changes; 6) renin-angiotensin-aldosterone system (RAAS) dysregulation. And we systematically discuss current prevention and treatment strategies and novel pathogenesis-based therapies for AIC: 1) dose reduction and change; 2) altering drug delivery methods; 3) antioxidants, dexrezosen, statina, RAAS inhibitors, and hypoglycemic drugs; 4) miRNA, natural phytochemicals, mesenchymal stem cells, and cardiac progenitor cells. We also offer a fresh perspective on the management of AIC by outlining the current dilemmas and challenges associated with its prevention and treatment.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"17 1","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141776328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Treatment Options: Uterine Sarcoma. 当前的治疗方案：子宫肉瘤。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-01 Epub Date: 2024-05-31 DOI: 10.1007/s11864-024-01214-3

Dana Lewis, Angela Liang, Terri Mason, James Stuart Ferriss

{"title":"Current Treatment Options: Uterine Sarcoma.","authors":"Dana Lewis, Angela Liang, Terri Mason, James Stuart Ferriss","doi":"10.1007/s11864-024-01214-3","DOIUrl":"10.1007/s11864-024-01214-3","url":null,"abstract":"Opinion statement: The cornerstone of treatment for uterine sarcoma, regardless of histologic type, remains en bloc surgical resection with total hysterectomy. In the case of incidental diagnosis during another procedure, such as myomectomy, where a hysterectomy was not performed initially, completion hysterectomy or cervical remnant removal is recommended. The completion of additional surgical procedures, including bilateral salpingo-oophorectomy and lymphadenectomy, remains nuanced. Bilateral salpingo-oophorectomy remains controversial in the setting of most subtypes of uterine sarcoma, except in the case of hormone-receptor positivity, such as in low grade endometrial stromal sarcoma, where it is indicated as part of definitive surgical treatment. In the absence of apparent nodal involvement, we do not recommend performing universal lymphadenectomy for patients with sarcoma. We recommend systemic therapy for patients with extra-uterine or advanced stage disease, high-grade histology, and recurrence. The most active chemotherapy regimens for advanced, high-grade disease remain doxorubicin or gemcitabine and docetaxol combination therapy. A notable exception is low grade endometrial stromal sarcoma, where we recommend anti-hormonal therapy in the front-line setting. Radiation therapy is reserved for selected cases where it can aid in palliating symptoms.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"829-853"},"PeriodicalIF":3.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

External Beam Radiotherapy in the Management of Uveal Melanoma. 治疗葡萄膜黑色素瘤的体外放射治疗。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-01 Epub Date: 2024-06-13 DOI: 10.1007/s11864-024-01212-5

Melek Tugce Yilmaz, Sezin Yuce Sari, Faruk Zorlu, Gozde Yazici

引用次数: 0

Promising Therapeutic Targets for Recurrent/Metastatic Anaplastic Thyroid Cancer. 复发性/转移性甲状腺无节细胞癌的有望治疗靶点

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-01 Epub Date: 2024-06-12 DOI: 10.1007/s11864-024-01219-y

Abdelrahman Sherif Abdalla, Mobeen Rahman, Saad A Khan

{"title":"Promising Therapeutic Targets for Recurrent/Metastatic Anaplastic Thyroid Cancer.","authors":"Abdelrahman Sherif Abdalla, Mobeen Rahman, Saad A Khan","doi":"10.1007/s11864-024-01219-y","DOIUrl":"10.1007/s11864-024-01219-y","url":null,"abstract":"Opinion statement: Anaplastic thyroid cancer presents formidable challenges, particularly in cases of recurrence or metastasis. Timely BRAF V600E testing is imperative at diagnosis, initially through immunohistochemistry, followed by comprehensive genomic profiling encompassing genes such as NTRK, RET, ALK, and assessment of tumor mutation burden (TMB). FDA-approved treatment options include dabrafenib and trametinib for patients with BRAF mutations, while those exhibiting high TMB may benefit from pembrolizumab. Further therapeutic decisions hinge upon mutational profile, urgency of response required, airway integrity, and access to targeted therapies There is growing use of immunotherapy for ATC based on published reports of activity, but currently there is no FDA approved agent for ATC. The off-label utilization of \"precision medicine\" combinations imposes a considerable financial strain, underscoring the necessity for further clinical trials to elucidate promising therapeutic avenues for this orphan disease. There is a pressing need for the development and support of clinical trials investigating genomically driven and immune-based therapies for anaplastic thyroid cancer.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"869-884"},"PeriodicalIF":3.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141307292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted Therapies in Low-Grade Serous Ovarian Cancers. 低级别浆液性卵巢癌的靶向治疗。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-01 Epub Date: 2024-06-13 DOI: 10.1007/s11864-024-01205-4

Anna Gonzalez, Christa I Nagel, Paulina J Haight

引用次数: 0

Neoadjuvant Immunotherapy in Non-melanoma Skin Cancers of the Head and Neck. 头颈部非黑色素瘤皮肤癌的新辅助免疫疗法

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-01 Epub Date: 2024-06-25 DOI: 10.1007/s11864-024-01197-1

Rami Ezzibdeh, Mohamed Diop, Vasu Divi

{"title":"Neoadjuvant Immunotherapy in Non-melanoma Skin Cancers of the Head and Neck.","authors":"Rami Ezzibdeh, Mohamed Diop, Vasu Divi","doi":"10.1007/s11864-024-01197-1","DOIUrl":"10.1007/s11864-024-01197-1","url":null,"abstract":"Opinion statement: Neoadjuvant immunotherapy will change the standard of care for advanced resectable cutaneous squamous cell carcinoma (cSCC) and possibly other non-melanoma skin cancers. With pathological complete response rates around 50% for cSCC in early studies, neoadjuvant therapy allows patients the possibility of significant reduction in tumor size, de-escalation of adjuvant therapy, and improved long-term outcomes. Patients must be carefully selected to ensure that there is a margin of safety with respect to resectability, such that if a tumor progresses on neoadjuvant therapy, there remains a curative surgical option that is acceptable to the patient. The optimal treatment paradigm is an area of active research, with many researchers questioning whether adjuvant therapy, or even local therapy, is necessary in patients who seem to have a complete response. The ability to predict who will respond will become even more critical to answer, as a significant number of patients do not want to risk their disease progressing, especially in cosmetically sensitive areas of the head and neck. Recent studies in melanoma show promise for improved response rates using combination therapies, and these strategies may apply to cSCC as well. The use of LAG-3 inhibitors or mRNA vaccine technology may further improve the utility of neoadjuvant strategies.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"885-896"},"PeriodicalIF":3.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141447421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Underlying Mechanisms of Thrombosis Associated with Cancer and Anticancer Therapies. 与癌症和抗癌疗法相关的血栓形成的基本机制。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-07-01 Epub Date: 2024-06-12 DOI: 10.1007/s11864-024-01210-7

Despoina Pantazi, Dimitrios Alivertis, Alexandros D Tselepis

{"title":"Underlying Mechanisms of Thrombosis Associated with Cancer and Anticancer Therapies.","authors":"Despoina Pantazi, Dimitrios Alivertis, Alexandros D Tselepis","doi":"10.1007/s11864-024-01210-7","DOIUrl":"10.1007/s11864-024-01210-7","url":null,"abstract":"Opinion statement: Cancer-associated thrombosis (CAT) has been identified as the second most prevalent cause of death after cancer itself. Moreover, the risk of thrombotic events in cancer patients increases due to anticancer drugs, such as tyrosine kinase inhibitors (TKIs). Venous thromboembolism (VTE) as well as arterial thromboembolic (ATE) events are present in CAT. Although VTE occurs more frequently, ATE events are very significant and in some cases are more dangerous than VTE. Guidelines for preventing thrombosis refer mainly VTE as well as the contribution of ATE events. Several factors are involved in thrombosis related to cancer, but the whole pathomechanism of thrombosis is not clear and may differ between patients. The activation of the coagulation system and the interaction of cancer cells with other cells including platelets, endothelial cells, monocytes, and neutrophils are promoted by a hypercoagulable state caused by cancer. We present an update on the pathomechanisms of CAT and the effect of anticancer drugs, mainly targeted therapies with a focus on TKIs. Considering the risk of bleeding associated with anticoagulation in each cancer patient, the anticoagulation strategy may involve the use of FXIa inhibitors, direct oral anticoagulants, and low-molecular-weight heparin. Further research would be valuable in developing strategies for reducing CAT.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"897-913"},"PeriodicalIF":3.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141307293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0